| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1464-410X.2005.05472.X |
| P698 | PubMed publication ID | 15839938 |
| P2093 | author name string | Hwang Choi | |
| Seok-Soo Byun | |||
| Eunsik Lee | |||
| Soo W Kim | |||
| Chongwook Lee | |||
| P2860 | cites work | A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 |
| The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line | Q41728447 | ||
| Decreased cisplatin uptake by resistant L1210 leukemia cells | Q43791058 | ||
| Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). | Q52832659 | ||
| Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. | Q53967094 | ||
| Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. | Q54447087 | ||
| P433 | issue | 7 | |
| P921 | main subject | glutathione | Q116907 |
| cisplatin | Q412415 | ||
| P304 | page(s) | 1086-1090 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | BJU International | Q4835773 |
| P1476 | title | Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities | |
| P478 | volume | 95 |
| Q51746123 | A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. |
| Q36589753 | Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches |
| Q24319826 | Altered antioxidant capacity in human renal cell carcinoma: role of glutathione associated enzymes |
| Q47163619 | Anticancer effect of S-allyl-L-cysteine via induction of apoptosis in human bladder cancer cells |
| Q28547244 | Chemical Library Screening and Structure-Function Relationship Studies Identify Bisacodyl as a Potent and Selective Cytotoxic Agent Towards Quiescent Human Glioblastoma Tumor Stem-Like Cells |
| Q28391411 | Co-administration of cisplatin and furosemide causes rapid and massive loss of cochlear hair cells in mice |
| Q34060461 | Conjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance. |
| Q35334366 | Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance. |
| Q59034916 | Evaluation of Platinum-Ethacrynic Acid Conjugates in the Treatment of Mesothelioma |
| Q55261457 | Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells. |
| Q34512480 | Expression profile of hydrogen sulfide and its synthases correlates with tumor stage and grade in urothelial cell carcinoma of bladder |
| Q37474341 | Glutathione S-transferases in kidney and urinary bladder tumors |
| Q36291188 | Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo |
| Q46268407 | Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis. |
| Q38996856 | Glutathione-mediated detoxification of halobenzoquinone drinking water disinfection byproducts in T24 cells |
| Q55476305 | Increased H2S and its synthases in urothelial cell carcinoma of the bladder, and enhanced cisplatin-induced apoptosis following H2S inhibition in EJ cells. |
| Q36557513 | Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death |
| Q43093356 | Isoenzyme profile of glutathione transferases in transitional cell carcinoma of upper urinary tract. |
| Q37539378 | Metabolomic Profiling of the Effects of Melittin on Cisplatin Resistant and Cisplatin Sensitive Ovarian Cancer Cells Using Mass Spectrometry and Biolog Microarray Technology |
| Q39732756 | Metal-based antitumour drugs in the post-genomic era: what comes next? |
| Q35758048 | Molecular mechanisms of resistance and toxicity associated with platinating agents |
| Q29247923 | NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells |
| Q38119531 | Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer |
| Q60926112 | Preliminary Evaluation of the Diagnostic Usefulness of Uroplakin 2 with an Assessment of the Antioxidant Potential of Patients with Bladder Cancer |
| Q34759878 | RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy |
| Q37984588 | Recent trends in cancer drug resistance reversal strategies using nanoparticles |
| Q47420453 | Systems Biology Approaches to Redox Metabolism in Stress and Disease States |
| Q91710491 | The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents |
| Q38391671 | The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. |
| Q37693895 | The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin |
| Q36650466 | Transcriptional up-regulation of SOD1 by CEBPD: a potential target for cisplatin resistant human urothelial carcinoma cells |
| Q36653012 | Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines |
| Q38647100 | Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines |
Search more.